Sulfamide, N-(((2S)-6-Chloro-2,3-Dihydro-1,4-Benzodioxin-2-Yl)Methyl)-
Depressive Disorder
Explore 78 assets in Depressive Disorder →Floatz Rating
CCC51/100
Confidence
Indicative
Sponsor
Janssen Research & Development, LLC
Modality
Small molecule
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
38Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT01114698CT.gov A Safety and Efficacy Study of JNJ26489112 in Patients With Treatment-Resistant Major Depressive Disorder | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Depressive Disorder
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Sulfamide, N-(((2S)-6-Chloro-2,3-Dihydro-1,4-Benzodioxin-2-Yl)Methyl)- (this asset) | Janssen Research & Development, LLC | P2 | CCC · 51 |
| Brexpiprazole | Dr. Albert Kar-Kin Chung | P4 | A |
| Saredutant | Sanofi | P3 | BBB |
| Jnj-54135419 | Chinese PLA General Hospital | P4 | BBB |
| Escitalopram | Poznan University of Medical Sciences | P4 | BBB |
| Fluoxetine | University of Oxford | P4 | BBB |
| VENLOR | Janssen Research & Development, LLC | P4 | BBB |
| Citalopram | Western University, Canada | P4 | BBB |
| Lithium, Elemental | Rakitzi, Stavroula | P4 | BBB |
+42 more in the Depressive Disorder cohort
Other indications for Sulfamide, N-(((2S)-6-Chloro-2,3-Dihydro-1,4-Benzodioxin-2-Yl)Methyl)-
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Photosensitive Epilepsy | — | P2 | CCC · 55 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Sulfamide, N-(((2S)-6-Chloro-2,3-Dihydro-1,4-Benzodioxin-2-Yl)Methyl)- in Depressive Disorder. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/sulfamide-n-2s-6-chloro-23-dihydro-14-benzodioxin-2-ylmethyl-depressive-disorder
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →